APA (7th ed.) Citation

Yang, L., Du, Z., Peng, Y., Zhang, W., Feng, W., & Yuan, Y. (2025). Mebendazole effectively overcomes imatinib resistance by dual-targeting BCR/ABL oncoprotein and β-tubulin in chronic myeloid leukemia cells. Korean Journal of Physiology & Pharmacology, 29(1), 67. https://doi.org/10.4196/kjpp.24.176

Chicago Style (17th ed.) Citation

Yang, Li, Zhuanyun Du, Yuhang Peng, Wenyao Zhang, Wenli Feng, and Ying Yuan. "Mebendazole Effectively Overcomes Imatinib Resistance by Dual-targeting BCR/ABL Oncoprotein and β-tubulin in Chronic Myeloid Leukemia Cells." Korean Journal of Physiology & Pharmacology 29, no. 1 (2025): 67. https://doi.org/10.4196/kjpp.24.176.

MLA (9th ed.) Citation

Yang, Li, et al. "Mebendazole Effectively Overcomes Imatinib Resistance by Dual-targeting BCR/ABL Oncoprotein and β-tubulin in Chronic Myeloid Leukemia Cells." Korean Journal of Physiology & Pharmacology, vol. 29, no. 1, 2025, p. 67, https://doi.org/10.4196/kjpp.24.176.